ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
AbbVie Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$282.68−2.74 (-0.96%)
Close on Oct 19, 2026
- Market cap
- $500.63B
- P/E (TTM)
- 79.9
- Dividend yield
- 2.35%
AbbVie Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All other | $2.63B | $3.03B | $3.04B | $4.14B | $5.02B | $5.12B | $2.07B | $2.41B | $876.00M | $1.20B | 4.3% | -13.4% |
| Synagis | – | – | – | – | – | – | – | – | $738.00M | $730.00M | – | – |
| Sevoflurane | – | – | – | – | – | – | – | – | $410.00M | $428.00M | – | – |
| Creon | – | – | – | – | – | – | – | – | $831.00M | $730.00M | – | – |
| Kaletra | – | – | – | – | – | – | – | – | $423.00M | $549.00M | – | – |
| Andro Gel | – | – | – | – | – | – | – | – | $577.00M | $675.00M | – | – |
| Synthroid | – | – | – | – | – | – | – | – | $781.00M | $763.00M | – | – |
| HUMIRA | – | – | – | – | – | – | – | – | $18.43B | $16.08B | – | – |
| Lupron | – | – | – | – | – | – | – | – | $829.00M | $821.00M | – | – |
| Duodopa | – | – | – | – | – | – | – | – | $355.00M | $293.00M | – | – |
| VIEKIRA | – | – | – | – | – | – | – | – | – | $1.52B | – | – |
| Imbruvica | – | – | – | – | – | – | – | – | $2.57B | $1.83B | – | – |
| HCV | – | – | – | – | – | – | – | – | $1.27B | $1.52B | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $46.60B | $43.03B | $41.88B | $45.71B | $43.51B | $34.88B | $23.91B | $21.52B | $18.25B | $15.95B | 76.2% | +8.3% |
| All other countries | $5.76B | $5.45B | $5.04B | $4.84B | $4.76B | $3.98B | $3.57B | $3.86B | $4.08B | $3.89B | 9.4% | +5.7% |
| Germany | $1.74B | $1.47B | $1.27B | $1.34B | $1.22B | $1.05B | $909.00M | $1.29B | $1.16B | $1.10B | 2.8% | +18.6% |
| Japan | $1.27B | $1.12B | $1.01B | $956.00M | $1.09B | $1.20B | $1.21B | $1.59B | $764.00M | $770.00M | 2.1% | +13.5% |
| Canada | $1.22B | $1.09B | $1.08B | $1.16B | $1.40B | $1.16B | $813.00M | $730.00M | $659.00M | $624.00M | 2.0% | +12.3% |
| China | $1.01B | $917.00M | $950.00M | $912.00M | $857.00M | $471.00M | $195.00M | $152.00M | – | – | 1.6% | +9.7% |
| France | $806.00M | $776.00M | $780.00M | $787.00M | $936.00M | $797.00M | $695.00M | $783.00M | $730.00M | $713.00M | 1.3% | +3.9% |
| United Kingdom | $626.00M | $522.00M | $417.00M | $462.00M | $497.00M | $509.00M | $372.00M | $855.00M | $807.00M | $776.00M | 1.0% | +19.9% |
| Spain | $609.00M | $528.00M | $501.00M | $506.00M | $519.00M | $453.00M | $472.00M | $611.00M | $521.00M | $589.00M | 1.0% | +15.3% |
| Italy | $580.00M | $511.00M | $484.00M | $444.00M | $506.00M | $379.00M | $372.00M | $652.00M | $475.00M | $523.00M | 0.9% | +13.5% |
| Brazil | $478.00M | $464.00M | $439.00M | $430.00M | $368.00M | $406.00M | $359.00M | $350.00M | $410.00M | $355.00M | 0.8% | +3.0% |
| Australia | $459.00M | $463.00M | $472.00M | $508.00M | $533.00M | $527.00M | $395.00M | $350.00M | – | – | 0.8% | -0.9% |
| Netherlands | – | – | – | – | – | – | $163.00M | $352.00M | $362.00M | $352.00M | – | – |
From the segment and revenue-disaggregation notes of AbbVie's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.